Page last updated: 2024-12-11
ro 48-5033
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Ro 48-5033: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6426755 |
| CHEMBL ID | 3901721 |
| SCHEMBL ID | 7205072 |
| MeSH ID | M0332079 |
Synonyms (27)
| Synonym |
|---|
| n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]-4-(1-hydroxy-2-methylpropan-2-yl)benzenesulfonamide |
| 4-(2-hydroxy-1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-benzenesulfonamide |
| FT-0669430 |
| unii-vz7ynj87xh |
| ro 48-5033 |
| hydroxybosentan |
| ro 48-8634 |
| benzenesulfonamide, 4-(2-hydroxy-1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)- |
| vz7ynj87xh , |
| 253688-60-7 |
| hydroxy bosentan |
| bosentan metabolite ro 48-5033 |
| SCHEMBL7205072 |
| FAJQMBCLPZWTQJ-UHFFFAOYSA-N |
| n-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]4-(2-hydroxy-1,1-dimethylethyl)benzenesulphonamide |
| n-[4-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-pyrimidinyl)pyrimidin-6-yl]-4-(2-hydroxy-1,1-dimethylethyl)benzenesulphonamide |
| AKOS030239680 |
| J-015960 |
| CHEMBL3901721 |
| FT-0669431 |
| FT-0669432 |
| CS-0081840 |
| HY-121385 |
| BCP15832 |
| hydroxybosentan pound>>ro 48-5033 pound>>ro 48-8634 pound>>bosentan metabolite ro 48-5033 |
| 4-(2-hydroxy-1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)(2,2'-bipyrimidin)-4-yl)benzenesulfonamide |
| 4-(2-hydroxy-1,1-dimethylethyl)-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2?-bipyrimidin]-4-yl]-benzenesulfonamide |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic profiles of bosentan and its pharmacologically active hydroxy metabolite, Ro 48-5033, were determined after each dose of bosentan." | ( Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects. Dingemanse, J; van Giersbergen, PL, 2005) | 0.55 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The oral bioavailability of bosentan was 43% to 48%, with a small interindividual variability of 20%." | ( Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. Birnboeck, H; Eggers, H; Hopfgartner, G; Jonkman, JH; Meyer, J; Schmitt, R; van Marle, S; Viischer, HW; Weber, C, 1999) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1323162 | Drug level in human liver microsomes treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Metabolism study and biological evaluation of bosentan derivatives. |
| AID1323173 | Retention time of the compound | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Metabolism study and biological evaluation of bosentan derivatives. |
| AID1323149 | Drug level assessed as human recombinant CYP3A4-mediated compound formation treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Metabolism study and biological evaluation of bosentan derivatives. |
| AID1323171 | Drug level assessed as human recombinant CYP2C9-mediated compound formation treated with bosentan at 5 uM in presence of NADPH after 30 mins by LC-MS/MS analysis | 2016 | European journal of medicinal chemistry, Oct-04, Volume: 121 | Metabolism study and biological evaluation of bosentan derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.57
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.57) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||